- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Alnylam Pharmaceuticals received regulatory approval for its lead drug in both the US and Europe.
2 reports, 1 independent
Updated Jul 2
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alnylam Pharmaceuticals received regulatory approval for its lead drug in both the US and Europe.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
Nothing else this week.
- FDA
Related events
- DEA guidance restricts state-licensed supply chains in Pennsylvania, relating to FDA-approved products.
- Steriwave requires FDA approval for US market.
- The FDA is involved in regulating drug approvals for GLP-1 Receptor Agonists.
- The FDA is a U.S. government agency, a basic descriptive fact about the regulator.
- FDA approved a drug based on UVA research led by Xuemei Huang.
Coverage
Newest first; wire copies grouped- BarchartProfits May Be Just Around the Corner for This Strong-Buy Pharma Stock Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ALNY has a 100% technical “Bu